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Introduction

The noroviruses are a group of related viruses in the Caliciviridae family. The name
“norovirus” comes from the first identified
member of this group, which was isolated
from diarrheal stools in 1972 during an outbreak of gastroenteritis in an elementary
school in Norwalk, Ohio. Subsequently,
noroviruses have been identified as the most
common cause of gastroenteritis in the U.S.
Noroviruses cause an estimated 23 million
cases of gastroenteritis each year in the U.S.,
more cases than are caused by all other viral,
bacterial, and parasitic agents combined.
Although noroviruses circulate year-round,
epidemics are most commonly recognized in
the winter and early spring.

Outbreaks of gastroenteritis due to noroviruses are especially common in congregate living
environments such as hospitals, long term
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care facilities, military barracks, summer
camps, and cruise ships. More recently,
noroviruses have been identified as the cause
of gastroenteritis outbreaks in jails, prisons,
and detention facilities. Norovirus outbreaks
have the potential for significant morbidity,
occasional mortality, and disruption in the routine operation of correctional facilities. This
article provides recommendations to assist
medical and custody personnel in the diagnosis, treatment, and containment of gastroenteritis outbreaks in the correctional setting.
Epidemiology

There are approximately 267,000,000
episodes of diarrhea among adults in the U.S.
each year, resulting in an estimated 612,000
hospitalizations and 3,000 deaths.1 An etiologic agent is identified in less than 10% of
these cases of diarrhea, and most persons
with acute diarrhea do not seek medical care
as a result of their illness. The very young, the
elderly, and the immunocompromised are
most affected by these illnesses.
Little has been published on the frequency
and etiology of diarrheal illness among the
incarcerated. Inmates often store food in their
cells or dorms for later consumption, and do

EDITOR

Dear Correctional Colleagues,

Each year, over 30 million cases of infectious diarrhea are diagnosed in the United States. The
overwhelming majority of these illnesses are due to viral pathogens, of which noroviruses are the
most common. Gastroenteritis outbreaks due to noroviruses have been reported in numerous settings, including schools, day care, restaurants, military barracks, and cruise ships. More recently, norovirus outbreaks have been diagnosed in correctional facilities.

Jails and prisons are perfect settings for the incubation and propagation of viral gastroenteritis. In
many ways, correctional facilities are functionally very similar to large cruise ships. Both house
hundreds if not thousands of transient residents and employees, and in both settings the residents utilize a common source for food, water, and laundry. Eating is the main recreational activity for both inmates and cruise ship passengers, and neither inmates nor cruise ship passengers
can depart their vessel at will.
One important difference complicating gastroenteritis outbreaks in the correctional setting is that
in most jails and prisons, inmates perform much of the essential work including culinary, housekeeping, grounds keeping, painting, and building maintenance. When a contagious disease outbreak such as viral gastroenteritis hits a correctional institution, the sudden loss of large numbers
of critical workers can severely impact day-to-day operations. Clearly, a prompt and effective
infection control response to contagious disease outbreaks is essential for both public health and
institutional safety and security.

This month’s issue of IDCR provides useful information and recommendations regarding the diagnosis and management of viral gastroenteritis in a correctional setting. It is our hope that by
preparing in advance, you, our correctional colleagues, will be better prepared to respond if /when
your facility is impacted by a gastroenteritis outbreak. As always, we welcome your feedback on
this and every issue, and encourage your recommendations regarding future infectious diseases
topics of interest.
Sincerely,
Joseph Bick, MD
Health Care Manager
Chief Deputy, Clinical Services
California Medical Facility
California Department of Corrections and Rehabilitation

not usually have access to refrigeration or
cooking appliances. Perishable food stuffs
can be a source of viral and bacterial gastroenteritis. In non-incarcerated institutional
settings, toxins and over 200 different bacteria, viruses, fungi, and parasites have been
identified as the source of diarrheal outbreaks.
Contaminated foods that have been linked to
diarrheal illness include pork2, chicken3,
ground beef4, milk5, unpasteurized apple
cider6-7, spinach8, eggs9, raspberries10,
onions11, raw nuts12, cantaloupe13, tomatoes14, soft cheeses15, and shellfish.16 Table
1 details the estimated total number of cases,
frequency of food-borne transmission, and
hospitalizations for the most common causes
of infectious organisms that can cause diarrhea in the U.S..
Signs and symptoms of noroviruses

The incubation period for norovirus following
infection is 12-48 hours. In healthy adults, clinical signs and symptoms are generally mild
and of short duration, usually 12-60 hours.
The illness can be more severe in the elderly
and others who have compromised immunity.
Rarely, severe dehydration due to norovirus
can be fatal. There are no known long-term
sequelae that result from norovirus infection.
Most of those who become ill experience the
sudden onset of nausea, vomiting, abdominal
cramps, and diarrhea. Constitutional symptoms including low-grade fever, headache,
chills, and myalgias are common. Patients
may experience only vomiting, commonly
referred to as winter vomiting disease.17
Diarrhea due to norovirus is usually watery,
and less severe than that caused by bacteria.
After recovery from illness due to norovirus,
individuals generally experience short-lived
immunity from recurrent illness and are therefore susceptible to repeated infection and disease within 6 months.
Transmission

Viral gastroenteritis can be introduced into a
jail or prison by employees, visitors, volunteers, or inmates who are transferred into the
facility. Less frequently, the virus can enter a
facility in contaminated food or water.
Norovirus is excreted in the stool of infected
persons, and can be shed from those who do
not become clinically ill. Excretion of virus precedes clinical illness and can persist for more
than a week after symptoms resolve.18-20
Noroviruses are readily spread from person to
person, by fomites, and from contaminated
environmental surfaces. The major route of
transmission is person to person (fecal-oral)
via hands contaminated with feces or emesis.
Norovirus is characterized by both a low infectious dose (<100 viral particles) and a high
attack rate among exposed persons.21 The
prolonged shedding of virus in the stool of
asymptomatic persons increases the likelihood of transmission by infected food handlers. Noroviruses can survive temperature
extremes from freezing to 140 F, and resists
killing by numerous disinfectants including relatively high levels of chlorine.22
Diagnosis

The first and most important step in the diagnosis of gastroenteritis is to remain vigilant,
especially when norovirus is known to be circulating in the outside community. Once viral
gastroenteritis is suspected, a rapid definitive
diagnosis of the causative agent will help
Continued on page 3
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(continued from page 2)

guide strategies for infection control and containment. An outbreak should be suspected if
> 2 inmates and/or employees concurrently
develop nausea, vomiting, and diarrhea. The
coexistence of vomiting and diarrhea is a useful clue to the presence of norovirus.

During a suspected outbreak, fresh stool
should be collected from six to twelve persons. In addition to testing specimens for
norovirus, stool should be cultured for campylobacter, salmonella, and shigella. If the stool
is bloody, it should also be tested for E. coli
0157:H7. Noroviruses cannot be cultured.
Options for diagnosis include direct visualization of viruses by electron microscopy (EM),
enzyme-linked immunosorbent assays (EIA)
for detection of virus in stool, the serologic
detection of a fourfold increase of specific
antibodies in acute- and convalescent-phase
blood samples, and the use of reverse-transcription polymerase reaction (RT-PCR).22-25
Because most adults have been infected with
norovirus at some point, the simple presence
of IgG antibody to norovirus is not useful in
terms of making a diagnosis. Serologic diagnosis, therefore, requires detecting either
virus-specific IgM antibodies or rising antibody titers in paired acute and convalescent
blood samples. The time lag involved in the
development of antibodies further limits the
usefulness of serological diagnosis. Currently
available EIAs are insufficiently sensitive and
specific to justify more widespread use at this
time. RT-PCR has significantly improved the
ability to rapidly and accurately diagnose
norovirus as the cause of gastroenteritis outbreaks. Most state public health laboratories
can test stool, emesis, rectal swabs, and environmental swabs for noroviruses utilizing RTPCR. Norovirus can be identified from stool
specimens taken between 2 and 7 days after
onset of symptoms. Once the presence of
norovirus has been confirmed within a facility,
additional cases can be diagnosed with sufficient accuracy utilizing clinical criteria. One
such definition, the Kaplan criteria, is quite
specific for viral gastroenteritis (see Table
2).26
Treatment

There are no specific antiviral therapies for
norovirus, and in most cases, oral re-hydration is sufficient. Occasionally, anti-emetics,
intravenous fluids, and/or electrolyte replacement therapy is necessary.
Infection control and containment

In the absence of prompt, thorough infection
control measures, norovirus can circulate
within an institution for an extended period of
time. Managing an institutional outbreak of
any contagious illness requires close collaboration between medical and custody staff.
During an outbreak of gastroenteritis, movement of inmates should be restricted as much
as possible. Even those who are not symptomatic may be incubating the virus, and can
spread the illness to others. Movement in and
out of the impacted housing units should be
limited. Viral gastroenteritis is more likely to
be spread in congregate settings. For this reason, strong consideration should be given to
temporarily suspending indoor group activities
such as visitation, school, and religious services. Inmates who are experiencing nausea
and/or vomiting should be confined to quarters until they have been asymptomatic for at
least 48 hours. Likewise, employees who are

ill should be encouraged to stay away from
the worksite until they have been without
symptoms for at least 48 hours. Sick inmates
should be fed in their cell, dorm, or housing
unit.

If possible, well inmates should eat in groups
by unit. The placement of alcohol-based hand
cleansers at the beginning of feeding lines
should be considered. Dining areas should be
cleaned and then wiped with bleach solution
between seatings.

Local operating procedures (LOPs) should
facilitate the closing of dormitories, yards, or
entire facilities to incoming inmates during
outbreaks of gastroenteritis and other communicable infectious disease such as varicella, tuberculosis, or scabies. Movement within
the institution should also be limited as much
as possible. This includes bed moves, visiting,
religious meetings, mental health groups, art
and music programs, hobby shop, and inmate
canteen. All non-essential inmate work should
be temporarily suspended. The only inmates
who should be allowed to work are those who
have been symptom free for at least 48 hours.
Food handlers should be monitored to ensure
that they perform frequent hand hygiene and
appropriately use gloves. LOPs should also
provide for the rapid screening and clearance
of critical inmate workers. Plans should be in
place to allow for the identification on short
notice of alternate workers for food handling,
laundry, and essential functions.

Housecleaning and hand hygiene

During outbreaks of gastroenteritis, employees and inmates should be regularly reminded about the importance of frequent hand
washing. Routine housecleaning efforts
should be intensified, including the cleaning of
walls, floors, table tops, handrails, sinks, toilets, and door knobs in day rooms, communal
restrooms, dining facilities, and showers. In
addition to environmental surfaces, medical
and custodial equipment such as blood pressure cuffs, stethoscopes, and restraint gear
should be routinely sanitized. Rapid response
teams should be created to remove and disinfect spills of body fluids such as feces or
vomit, especially in common areas. The body
fluid should be removed, and the area disinfected by the application of a bleach solution
for a minimum of ten minutes. After ten minutes, the excess solution should be wiped up.
Mop buckets should be disinfected and mop
heads cleaned or discarded after each
episode of cleaning up a contaminated spill.
Mops and other cleaning materials that are
used for cleaning up spills should not be
reused for routine cleaning in other areas. All
mop heads should be changed and either
laundered or discarded at least once daily.
Housecleaners should utilize wear personal
protective equipment to include masks, disposable gowns, and gloves.

Based upon studies of viral killing with other
related calciviruses, chlorine bleach is the
only disinfectant that is fully endorsed by the
CDC for use against norovirus (see 101).
Therefore, bleach-containing solutions should
be used for surface cleaning and mopping.
The solution should be mixed fresh each day
utilizing 1 cup of bleach to 3 gallons of water.
This disinfectant solution must be changed
frequently to prevent dirt and organic materials from inactivating the activate disinfectants.
The 101 Section provides directions for mixing bleach solutions. Unfortunately, bleach is
caustic and could potentially be used in an
assault. Additionally, bleach can be used to
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change the color of inmate clothing and/or
alter personal appearance by dying hair. For
these reasons, it is important to work in
advance with custody to develop procedures
that allow for the safe use of bleach when it is
legitimately necessary.

Inmates and employees should be encouraged to frequently wash their hands with soap
and water, or an alcohol-based hand rub.
Healthy inmates should be allowed access to
the showers first, followed by those inmates
who are ill. Showers should be cleaned and
disinfected with bleach solution after being
used by sick inmates.

Education and communication

Educational efforts should be directed at
inmates, employees, visitors, volunteers, and
the public. The use of multiple teaching methods including handouts, overheads, in-house
cable television channels, and posters is
encouraged. Inmate peer educators can be a
valuable resource, as can inmate advisory
counsels, inmate family groups, and labor
unions. Educational materials should be provided in multiple languages, and be written to
accommodate those with low levels of literacy. Daily briefings should be provided to key
medical and custody stakeholders. The public
information officer should be prepared to communicate with the media and the surrounding
community if called upon to do so.

Tracking the outbreak

Tracking of all individuals (inmates and
employees) greatly facilitates the management of outbreaks of viral gastroenteritis and
other communicable conditions. Each day, a
list should be updated with essential information to include at least the inmate name, number, housing, date symptoms began and
ended, date of confinement to quarters and
release, date specimens collected, and
results of specimens. This information should
be collated each day into a new updated
report that can be shared with key outbreak
managers (see Table 3). Each day, a nursing
team should conduct face-to-face evaluations
of any inmates who are experiencing symptoms consistent with gastroenteritis. This is to
include new cases and those who are confined to quarters. Nursing staff should carefully monitor these individuals, and rapidly bring
them to medical attention if they require additional medical intervention such as intravenous fluid replacement.
Conclusions

Outbreaks of gastroenteritis commonly occur
in congregate living environments such as
jails and prisons. Most of these outbreaks are
due to viruses, with noroviruses being the
most common etiology. Gastroenteritis outbreaks can result in a large number of sick
inmates and employees, significant morbidity,
and major disruption to normal programming.
A coordinated response involving on-site
medical and custody staff, augmented as
needed by local, county, and state public
health resources, can be quite effective in mitigating the impacts of gastroenteritis outbreaks. Jail and prison administrators would
be prudent to establish policies and procedures in advance of these outbreaks to help
facilitate the best possible outcome.

Continued on page 4
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Table 1:

Reported and estimated illnesses, frequency of food-borne transmission, and hospitalizations for
known food-borne pathogens, United States- 2004
ORGANISM

ESTIMATED TOTAL CASES

% FOOD-BORNE

HOSPITALIZATION RATE

Norwalk-like viruses

23,000,000

40

N/A

Astrovirus

3,900,000

1

N/A

VIRUSES
Rotavirus

Hepatitis A
BACTERIA

Campylobacter spp

Salmonella, non-typhoidal
Shigella spp.

Clostridium perfringens
Yersinia enterocolitica

Escherichia coli O157:H7
PARASITES

Giardia lamblia

Cryptosporidium parvum

3,900,000

1

N/A

5

0.130

2,453,926

80

0.102

448,240

20

0.139

83,391

1,412,498

95

248,520

100

73,480

85

96,368

2,000,000
300,000

90

10
10

0.221
0.003
0.242
0.295

N/A

0.150

Source: Modified from Diagnosis and Management of Food-borne Illnesses: A Primer for Physicians and Other Health Care Professionals. MMWR 2004; 53 (No. RR-4)

Table 2: The Kaplan Criteria for determining whether an outbreak of gastroenteritis is of viral origin
Stool cultures negative for bacterial pathogens
Mean (or median) duration of illness - 12-60 hours
Vomiting in greater than or equal to 50 percent of cases
Mean (or median) incubation period (if known) of 24-48 hours

Continued on page 5
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Transmission electron micrograph of noroviruses. The bar = 50 nm

Source: F.P. Williams, U.S. EPA

Source: Recommendations for the Prevention and Control of Viral Gastroenteritis Outbreaks in California Long-Term Care Facilities (CDHS, October 2006).
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Abdominal cramps (Y/N)

Diarrhea (Y/N)
Watery (Y/N)
Bloody (Y/N)

Resident/Staff
location

Nausea (Y/N)

Projectile (Y/N)

Vomiting (Y/N)

Highest Temperature

Date onset illness

Room # Bed Designation

Resident/Staff
identification

Unit

Building

Sex (M/F)

Age

Name
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Table 3: Sample Case Log of Residents and Staff with Acute Gastrointestinal Illness
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101: Preparation of Bleach Disinfectant Solutions

500 ppm (0.05%)
Dilutions of standard (5.25%)
bleach prepared fresh for use
within 24 hours

Bleach/water

Dilutions of standard (5.25%)
bleach prepared fresh for use
within 24 hours

Bleach/water

Preparation

Preparation

Desired Chlorine Concentration
1000 ppm (0.1%)

1000 ppm (0.5%)

1:100

1:50

1:10

2 1/2 tablespoons (1/6 cup)
bleach in a gallon of water

5 tablespoons (1/3 cup)
bleach in a gallon of water

25 tablespoon (1 2/3 cup)
bleach in a gallon of water

1:50

1:25

1:5

5 tablespoons (1/3 cup)
bleach in a gallon of water

10 tablespoons (2/3 cup)
bleach in a gallon of water

50 tablespoons (3 1/3 cup)
bleach in a gallon of water

“Ultra” concentrations of bleach contain 6-7.35% hypochlorite and are not recommended to avoid producing higher than intended concentrations of
chlorine.
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48-Week raltegravir Data Confirm Salvage Safety, Potency, and
Tolerability

California Governor Requests $7 Billion for Prison Health Care

Raltegravir (Isentress) is the first FDA approved medication in a new
class of HIV drugs called integrase inhibitors. raltegravir is approved for
use in combination with other agents in patients who have developed
resistance to other antiretroviral therapy.

In 2001, a class action law suit was brought against the State of California
over the quality of medical care in the state's 33-prison system. The court
found that the care was a violation of the Eighth Amendment of the U.S.
Constitution, which forbids cruel and unusual punishment of the incarcerated.

Interim analyses at 16 and 24 weeks demonstrated that raltegravir produced superior efficacy compared with placebo in all 3 endpoints.
Approximately 75% of study participants experienced a decrease in HIV
viral load to <400, and approximately 60% reached a viral load of <50. On
average, CD4 counts increased by 80/mm3.

In his 2008/2009 budget, California Governor Arnold Schwarzenegger
has requested an additional $7 billion for building and upgrading prison
medical and mental health care facilities. Most of the $7 billion
Schwarzenegger is requesting would be borrowed. This request is in
addition to $7.4 billion in bonds voters approved last year to pay for prison
and jail construction, and comes at a time that California is wrestling with
a projected budget deficit of $16 billion.

The efficacy and safety of raltegravir is being evaluated in two ongoing
phase III, randomized, double-blind, placebo-controlled trials
(BENCHMRK 1 and 2). At entry, all patients were failing treatment and
demonstrated resistance to three classes of antiretroviral therapy. The 3
primary endpoints for both studies are changes in CD4 count from baseline, percentage of participants with viral load reduction to <400
copies/ml, and percentage of participants with viral load reduction to <50
copies/ml.

More recently, combined 48 week data from BENCHMRK 1 and 2 was
presented at the 15th Conference on Retroviruses and Opportunistic
Infections (CROI) (Cooper et al, poster #788). The 48 week data demonstrated that the response rates exhibited at weeks 16 and 24 have been
maintained to 48 weeks. Encouragingly, this agent has shown benefit
even in a significant number of patients who have low CD4 counts, highly resistant virus, and viral loads >100,000.

Of note, approximately 45% of patients who had no other active agents in
the optimized background therapy (as assessed by genotype and phenotype) maintained <50 copies/ml at 48 weeks. Although this response in
highly resistant patients is encouraging, every effort should still be made
to utilize raltegravir in combination with at least one other fully active
agent. raltegravir has been very well tolerated, on par with placebo.
Thusfar, treatment with raltegravir has not lead to cross resistance to
other approved antiretroviral agents.

Data was also presented at CROI regarding the substitution of raltegravir
for efuvirtide (Fuzeon) in patients who have an undetectable viral load.
(Harris et al, Abstr. 99). Although this study involved only 29 patients with
a maximal follow-up of only 4 months, all patients maintained an undetectable HIV viral load. If confirmed by further data, this may provide a
useful option for those patients who are unwilling or unable to continue
with a Fuzeon based regimen.

Mascolini, Mark. 15th Conference on Retroviruses and Opportunistic
Infections, Boston, February 3-6 2008.

The state settled the suit in 2002, agreeing to a range of remedies that
would bring prison medical care in line with constitutional standards.
However, the court ruled that the state failed to comply with the settlement, and therefore established a Receivership in June 2005. This
Receivership has full authority to manage medical care operations in the
prison system.

"Medical facilities, when they exist at all, are in an abysmal state of disrepair. Basic medical equipment is often not available," CDCR Receiver
Clarke Kelso said in a strategic plan he released last month. "Indeed, it is
a misnomer to call the existing chaos a 'medical delivery system'—it is
more an act of desperation than a system."

Don Thompson. Associated Press Writer; San Jose Mercury News;
California Prison Health Care Receivership Corp,
http://www.cprinc.org/about.htm

Trials of NIH HIV Vaccine Candidate Scaled Down After Failure of
Merck Vaccine
In September 2007, Merck abruptly halted a large-scale clinical trial of its
candidate HIV vaccine after initial analysis suggested that the vaccine not
only failed to prevent HIV infection in participants or delay the virus’s progression to AIDS, but might have made some participants more susceptible to HIV infection. Subsequently, the NIH has announced that it will
significantly scale down its trials of the PAVE-100 HIV vaccine from the
original proposal.

The vaccine candidate uses a combination of the cold virus adenovirus-5
and DNA in order to stimulate cells to produce proteins that will generate
an immune response against HIV. Merck researchers found that individuals who had a high baseline immunity to adenovirus-5 were at an
increased risk of contracting HIV.
Continued on page 4
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SAVE THE
DATES

2008 National Health Care for the
Homeless Conference and Policy
Symposium
Phoenix, AZ
Country: United States
June 11-14, 2008
Visit: http://www.nhchc.org/2008
conference/2008conference.html

Tuberculosis Intensive - Seattle
Seattle, WA
June 19-20, 2008
Visit: http://www.nationaltbcenter
.edu/training/tb_intensive.cfm

2008 Viral Hepatitis Health
Leadership Summit
Baltimore, MD
June 20, 2008
Visit: http://www.hepfi.org/

TB Nurse Case Management
Albuquerque, NM
July 22-23, 2008
Visit: http://www.heartlandntbc.org/
training.asp

XVII International AIDS
Conference (AIDS 2008)
Centro Banamex Convention and
Business Centre
M_xico City, M_xico
August 3-8, 2008
Visit: http://www.aids2008.org/

American Correctional
Association - 138th Congress
of Correction
New Orleans, Louisiana
August 8-13, 2008
Visit: http://www.aca.org/
conferences/summer08/home.asp

The 48th Annual ICAAC/IDSA
46th Annual Meeting
Washington, DC
October 25-28, 2008
Visit: http://www.icaacidsa2008.org/

Correctional Mental Health
Seminar
Las Vegas, NV
July 13-14, 2008
Visit: http://www.ncchc.org/education
/mental/index.html

National Conference on
Correctional Health Care
Chicago, IL
October 18-22, 2008
Visit: http://www.ncchc.org/education
/national2008.html
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Trials of NIH HIV Vaccine Candidate Scaled Down After Failure of Merck Vaccine...
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Anthony Fauci, director of NIH’s National Institute of Allergy and Infectious Diseases, has announced that future
trials of the candidate vaccine will not include anyone who has a high immunity to the cold adenovirus-5, so as
to minimize risk of HIV-infection to the trial’s participants. As part of the scale down, the trial will only include 2,000
participants from Africa and the U.S., a marked decrease from the original 8,500 planned participants. The trial
will require that male participants be circumcised, a practice that has recently been found to reduce risk of HIVinfection in men.

The International AIDS Vaccine Initiative, however, has announced plans to withdraw from the planned trials.
The group had intended to enroll 1,000 African participants in the trial, but has stated that the new trial is “a safety unknown” given the general lack of “clear understanding of why” the Merck vaccine candidate failed. Similarly,
many researchers have questioned new HIV vaccine trials in the wake of the unanticipated failure of the Merck
vaccine.
Kaiser Daily HIV/AIDS Report. Trials of NIH HIV Vaccine Candidate Scaled Down After Failure of Merck. March
25, 2008. http://www.kaisernetwork.org/Daily_reports/rep_index.cfm?DR_ID=51109

HPV in Heterosexuals, Prevalence and Factors Associated with Anal Lesions Mediated by HPV in Men
with HIV/AIDS

Researchers at the University Hospital in Pemambuco, Brazil are investigating the relationship between human
papillomavirus and anal lesions in men who are HIV-positive. Such co-infections with HIV and HPV are relatively widespread, as both are transmitted through sexual contact. Persons who are co-inected with these viruses
stand a greater likelihood of having premalignant and malignant anogenital lesions due to HIV’s compromising
effect on the immune system. While antiretroviral therapy has been effective in reducing the prevalence of opportunistic infections in persons infected with HIV, such treatment has had little effect in preventing anogenital
lesions.

In response to a lack of information in this field, researchers in northern Brazil developed a study population of
sixty HIV-positive men who, on average, had been living with HIV-infection for 6.8 years. Approximately 88% of
the men had been on highly active antiretroviral therapy for over six years. 43.3% of the study’s participants were
homosexual, while heterosexuals comprised 41.7% of the patients. The remaining 15.0% of the patients identified themselves as bisexual. Over 60% of all participants reported having had receptive anal intercourse, and all
participants submitted to a series of diagnostic tests for anogenital lesions.
Anal lesions were found in 16.7% of patients according to anal cytology, 35.0% according to anoscopy under colposcopic vision, and 23.3% according to anal biopsy. Over 85% of patients with abnormal histology were homosexuals or bisexuals and 78.6% of patients with anal lesions reported having had 10 or more same-sex partners
during their lifetime. Interestingly, CD4 cell count, viral load, and use of antiretroviral therapy seemed to have little impact on anal biopsy results.

The results of this study call in to question the use of anal cytology as the sole screening test for anal lesions.
Researchers suggest that the screening process also include anoscopy under colposcopic vision and biopsy as
a means of preventing and diagnosing anal lesions in men co-infected with HIV and HPV. While a large portion
of this study’s participants were homosexual or bisexual men, it is important to note that HIV/HPV co-infected heterosexual men with no reported history of receptive anal intercourse can also be at risk for anal cancer.

HPV in Heterosexuals. Prevalence and factors associated with anal lesions mediated by human papillomavirus
in men with HIV/AIDS. H R Lacerda and R R Barros. International Journal of STD & AIDS 2008;19:192-96.

Is Jail Screening Associated With a Decrease in Chlamydia Positivity among Females Seeking Health
Services at Community Clinics?
San Francisco, 1997-2004

San Francisco’s Jail Health Services has partnered with the Center for Disease Control and Prevention’s
Epidemic Intelligence Service in order to research how chlamydia screening and treatment programs in jails
would impact chlamydia positivity among females attending neighborhood medical clinics.

Although chlamydia can lead to long-term health problems in women, including infertility and pelvic inflammatory disease, the infection is generally asymptomatic and can go undetected if a patient is not tested for it. Like
most sexually transmitted infections (STIs), chlamydia disproportionately infects both incarcerated persons and
ethnic and racial minorities. As such, programs to screen and treat adults entering jail for chlamydia might
decrease chlamydia positivity in the neighborhoods where a substantial number of persons in jail usually reside.

In order to determine the impact of chlamydia screenings in jail on neighborhoods in San Francisco, researchers
compared jail screening rates by neighborhood from 1997 to 2004 to chlamydia positivity in two neighborhood
health clinics. Approximately 45% of eligible males and 38% of eligible females entering jail during the eight year
evaluation period were tested for chlamydia, resulting in 6.1% positivity in males and 7.3% positivity among
females. Of those inmates who tested positive for chlamydia, an estimated 81% were known to have received
treatment for their infection. Testing for chlamydia was conducted at health Clinics O and S among females aged
15 to 25 years. Females tested at Clinic S were predominantly black and patients tended to reside in neighborhoods with jail testing density. In contrast, only a small percent of females tested at Clinic O were black and from
neighborhoods with high jail testing density.
Chlamydia positivity at Clinic S decreased significantly over the evaluation period, from 16.1% in 1997 to 7.8%
in 2004. In contrast, positivity remained constant at 4.7% in patients at Clinic O.

These results demonstrate that chlamydia screening in jail can have a significant impact on chlamydia positivity
in the outside community. Moreover, chlamydia screening was widely accepted amongst persons entering jail
and the vast majority of those who tested positive were able to be treated, despite the short length of jail stays.
This study underscores both the feasibility and importance of STI screening in jail as incarceration represents an
important opportunity to test and treat at-risk populations.

Is Jail Screening Associated With a Decrease in Chlamydia Positivity among Females Seeking Health Services
at Community Clinics? – San Francisco, 1997-2004. Barry, P et al. Sexually Transmitted Diseases. 2008;35(12).
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SELF-ASSESSMENT TEST

FOR

CONTINUING MEDICAL EDUCATION CREDIT

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing
Medical Education through the joint sponsorship of Nova Southeastern University Health Professions Division, Inc. (NSU) and IDCR. NSU is accredited by the ACCME to provide continuing medical education for physicians.

Nova Southeastern University Health Professions Division designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™.
The target audience for this educational program is physcians. Physicians should only claim credit commensurate with the extent of their
participation in the activity. Statements of credit will be mailed within 6 to 8 weeks following the program.
Objectives:

The learner will be able to describe the epidemiology, transmission, symptoms, and signs of noroviruses.
The learner will be able to explain the most effective norovirus infection control and containment methods.

The learner will be able to discuss useful ways to educate inmates, health care professionals, and administrative staff on the prevention and
containment of noroviruses.
1. The major route of transmission for the noroviruses is person to
person (fecal-oral) via hands contaminated with feces or emesis.
True or False

2. Which of the following is NOT a useful serologic indicator of
acute norovirus infection:
A. The presence of IgG antibody to norovirus
B. The presence of virus-specific IgM antibodies
C. Rising antibody titers in paired acute and convalescent
blood samples

3. Which of the following may be useful to prevent further
transmission of the norovirus within a correctional institution
A. Temporarily suspending indoor group activities such as
visitation, school, and religious services
B. Increasing hand washing of inmates and employees
C. Encouraging employees who are ill to stay away from
the worksite until they have been without symptoms for
1 or 2 weeks
D. Both A and B

4. The use of bleach as a disinfectant should be discouraged
because it has not been shown to be useful in killing noroviruses.
True or False

5. According to Table 2 which of the following is NOT a criteria for
determining whether an outbreak of gastroenteritis is of viral origin
A. Mean or median of incubation period (if known) of
24-28 hours
B. Vomiting in less than 25% of cases
C. Stool cultures negative for bacterial pathogens
D. None of the above

5 Excellent

IDCR EVALUATION

4 Very Good

3 Fair

2 Poor

1 Very Poor

1. Please evaluate the following sections with respect to:
Main Article

educational value
5 4 3 2 1

clarity
5 4 3 2 1

Save the
Dates

5 4 3 2 1

5 4 3 2 1

In the News

5 4 3 2 1

5 4 3 2 1

2. Do you feel that IDCR helps you in your work?
Why or why not?

3. What future topics should IDCR address?
4. How can IDCR be made more useful to you?
5. Do you have specific comments on this issue?

In order to receive credit, participants must score at least a 75% on the post test and submit it along with the credit
application and evaluation form to the address/fax number indicated. Statements of credit will be mailed within 4-6 weeks
following the program.

Instructions:

• Applications for credit will be accepted until
June 30, 2009.

• Late applications will not be accepted.
• Please anticipate 4-6 weeks to recieve your certificate.

Please print clearly as illegible applications will result in a delay.

Name:

_________________________________________________ Profession: __________________________________

License #: ___________________________________ State of License: __________________________________________
Address: ____________________________________________________________________________________________

City: ________________________ State: ________ Zip: ________________________ Telephone: ___________________
Please check which credit you are requesting

___ ACCME or

___ Non Physicians

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------I certify that I participated in IDCR monograph June 2008 Issue

Please fill in the number of actual hours that you attended this activity.
Date of participation: ______________________

Number of Hours (max. 1): ___________________

Signature: _________________________________________________

Please Submit Completed Application to:

Infectious Disease in Corrections Report
146 Clifford Street, Providence, RI 02903
or fax it to (401)272-7562

